Zemvax Confirms GV1001's Potential to Prevent Alzheimer's Disease in Periodontitis Patients

GemVax & Kael announced on the 5th that a paper confirming the preventive effects of GV1001 on periodontitis, atherosclerosis caused by periodontitis, and Alzheimer's disease was published in the International Journal of Molecular Sciences (IJMS).

The paper on the prevention of periodontitis and systemic disorders induced by Porphyromonas gingivalis (Pg) in an ApoE-deficient animal model with GV1001 was published in IJMS on the 1st. It addresses the therapeutic and preventive effects of GV1001 on periodontitis, atherosclerosis caused by periodontitis, and Alzheimer's disease. This study is an extension of the research published in August last year titled "Suppression of the severity of periodontitis and vascular lipid deposition related to periodontitis in animal models with GV1001." The authors include eight researchers led by Professor Emeritus No-Hee Park from UCLA School of Dentistry.

Periodontitis is known to affect approximately 10-15% of the adult population worldwide. When severe, periodontitis is identified as a risk factor causing various diseases such as diabetes, atherosclerosis, and dementia, beyond simply tooth loss.

According to the study, administration of GV1001 to ApoE-deficient Pg-induced periodontitis mice suppressed the onset of periodontal disease and vascular inflammation. Notably, the accumulation of biomarkers related to Alzheimer's disease was reduced following GV1001 administration.

The research team explained, "GV1001 showed effects in reducing vascular inflammation and lowering total cholesterol and low-density lipoprotein (LDL) in the blood, thereby preventing the occurrence of atherosclerosis." They added, "It reduced the accumulation of amyloid beta and tau, the main biomarkers of Alzheimer's disease," emphasizing that "this demonstrates the therapeutic and preventive effects of GV1001 on Alzheimer's disease in patients with periodontitis."

A GemVax representative stated, "Considering the association between periodontitis and the onset of Alzheimer's disease, the research results showing reduced accumulation of amyloid beta and tau in the periodontitis animal model are very positive signals for the development of the Alzheimer's disease treatment GV1001."

GemVax is conducting preclinical and clinical trials to verify various effects of GV1001, including anti-aging, antioxidant, and anti-inflammatory properties. Along with preclinical trials for various indications, global Phase 2 clinical trials for Alzheimer's disease treatment are progressing smoothly in the United States and Europe, as well as domestic Phase 2 clinical trials for progressive supranuclear palsy.

This content was produced with the assistance of AI translation services.